Board of
Governance

Dame Carol is currently , the Government’s independent advisor on drug misuse. She is also Chair of the British Library, the Centre for Ageing Better, and Think Ahead, the Government’s fast-stream training programme for Mental Health Social Workers. She is a member of RAND Europe’s Council of Advisers.

In 2019 she completed a seven year term as Principal of Newnham College in Cambridge University where she was a Deputy Vice-chancellor.

She is a past President of the Royal College of Physicians of the Academy of Medical Royal Colleges past Chair of the Nuffield Trust for Health Policy and a previous She has been a trustee of the National Portrait Gallery.

Professor of Rheumatology and Medicine, University of Florence, Italy
Scientific Consultant at IRCCS- Hospital San Raffaele, Milan, Italy
Marco Matucci-Cerinic is Full Professor of Rheumatology and Medicine at the Department of Experimental and Clinical Medicine, Chairman of the IRB committee of the Tuscan region. Is a Scientific Consultant at Hospital San Raffaele. He works in the Rheumatology Division of the Careggi University Hospital of Florence. The professor is a member of the prestigious British Royal College of Physicians, the American College of Rheumatology, the Italian Society of Rheumatology and is an honorary member of the British Society of Rheumatology.

Dr Matucci-Cerinic has published more than 1300 peer review manuscripts widely in the field of rheumatology, particularly on the pathogenesis, clinical features and treatment of scleroderma, on spondyloarthritis and on osteoarthtritis. He has also served on various international and national committees_ in particular as EULAR General Secretary, as executive secretary of ILAR, as Chairman of the European Scleroderma Trial and Research Group (EUSTAR) and vicepresident of the Scleroderma Clinical Trial Consortium (SCTC) . He is currently chairman of the World Scleroderma Foundation (WSF) and Editor in Chief of the Journal of Scleroderma & Related Diseases (JSRD) . He is also Associate Editor of Arthritis Research & Therapy and Clinical & Experimental Rheumatology, past Associate Editor and Co-Editor of Rheumatology. He serves on the boards of Annals of the Rheumatic Diseases, Rheumatology, Journal of Rheumatology, Scandinavian Journal of Rheumatology and other rheumatology journals.

Daniel E Furst MD
Carl M Pearson Professor of Rheumatology
Univ of Cal at Los Angeles
1000 Veteran Ave Rm 32-59
Los Angeles Ca 90095-1670
Tel: :310-794-9504
Fax: 310-206-8476
E-Mail: defurst@mednet.ucla.edu

Daniel E. Furst is Professor of Medicine at the University of California(emeritus), Los Angeles (UCLA), Medical Center, David Geffen School of Medicine, Department of Medicine, Division of Rheumatology. He is also Adjunct professor at the university of Washington, Seattle Washington and Research Professor at the University of Florence, Florence, Italy.

He has part time practices at the Arthritis Associates of Southern California and the Seattle Rhuematology Associates in Seattle Washington.

Dr. Furst received his MD from Johns Hopkins University, where he also completed his internship and residency. He completed two fellowships, one in Rheumatology at UCLA Medical Center, and a second in clinical pharmacology at the University of California, San Francisco Medical Center.

After serving as assistant professor of medicine/rheumatology at the UCLA Medical Center and associate professor of internal medicine/Rheumatology at the University of Iowa Carver College of Medicine, Dr. Furst became clinical professor in the Department of Medicine, Division of Rheumatology and Connective Tissue Research at the University of Medicine and Dentistry of New Jersey, and director of AI/P Clinical Research at Ciba Geigy Pharmaceuticals. He then moved to Seattle, where he was clinical professor of medicine at the University of Washington, then director of clinical research programs and director of the Arthritis Clinical Research Unit at the Virginia Mason Medical Center. He took up his position at UCLA in 2002 and became emeritus in 2015. At that time he took on his several other positions and practices, thus both enlarging his research and clinical practices.

He is on the national medical advisory board of the Scleroderma Foundation, the scientific advisory board of the Arthritis Foundation, and the board of directors for the foundation of the Collaboration of Research Rheumatologists of North America. He is on the editorial review board of numerous clinical pharmacology and rheumatic disease journals. He has written over 800 original articles/reviews/chapters and written or edited 14 books on rheumatic diseases.

Thomas Krieg, University of Cologne, Cologne, Germany
Kerpener Str. 62
50937 Köln, Germany
Tel: +49-221-478 8 22 45
E-Mail: thomas.krieg@uni-koeln.de

Professor Thomas Krieg is Director and Chairman in the Department of Dermatology at the University of Cologne, in addition to being the Dean of the Medical Faculty at the University of Cologne. He has extensive experience in the field of dermatology, as well as serving for several years as Director of the Center for Molecular Medicine in Cologne. He is a Fellow of the Royal College of Physicians, London, and was awarded honorary membership of the Polish and Hungarian Dermatological Societies. Professor Krieg has an extensive publication record and has co-written many papers on systemic sclerosis and wound healing, particularly with regards to the molecular mechanisms involved in pathogenesis.

Is Susan Cheney Professor of Experimental Medicine. He graduated in Italy and completed his PhD and postdoctoral studies in the Scleroderma Centre of Thomas Jefferson University, in Philadelphia, PA. In 2009 he moved to UK to found and lead the Raynaud’s and Scleroderma Programme in the NIHR Biomedical Research Centre of the University of Leeds. The Scleroderma Programme in Leeds is a large, patient centred translational research programme with research spanning from basic aspects of the pathogenesis of Systemic Sclerosis to biomarkers led precision medicine and early intervention for the prevention of internal organ complications of the disease. He has been EUSTAR member since 2006 in Philadelphia first and then Leeds . From 2019 to 2022 he served as EUSTAR counsellor, working on the EUSTAR platinum project. This is a networked subgroup of patients within the EUSTAR database with high quality clinical data and complete biosample availability, to inform target validation and biological endpoints in early phase clinical trials.

Dr. Masataka Kuwana is a professor and chairman of Allergy and Rheumatology at Nippon Medical School, and a director of Scleroderma/Myositis Center of Excellence at Nippon Medical School Hospital in Tokyo, Japan.
He was trained at Keio University and joined the Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, as a postdoctoral fellow. Dr. Kuwana has spent his professional career focusing on basic and clinical aspects of systemic sclerosis, myositis, and a variety of systemic and organ-specific autoimmune diseases. He has published more than 510 peer-reviewed scientific articles and written more than 12 book chapters. He serves as Editor-in-chief of Journal of Scleroderma and Related Disorder and Modern Rheumatology.
His main research interests include systemic sclerosis, idiopathic inflammatory myopathies, pulmonary complications of connective tissue diseases, and autoimmunity.

Dinesh Khanna, MD, MSc, is Professor of Medicine and Director, University of Michigan Scleroderma Program. He holds the Frederick G.L. Huetwell Professorship in Rheumatology. Dr. Khanna has published over 500 peer-reviewed articles and book chapters. He leads one of the largest scleroderma programs in US. He received the 2015 Henry Kunkel Young Investigator Award from the American College of Rheumatology and was inducted in the 2023 American Society for Clinical Investigation. He has been included in the Stanford’s Top 2% Scientists list from 2021-2023